Drug Utilization Study Of Diuretics In Hepatic Cirrhosis Patient With Ascites At Airlangga University Hospital Surabaya

Yudistira Nurrizky Grahitaning Putra Rohmaana, Ayudika Permatasari, An Nisa Nur Laila, M. Dzul Azmi A.A.

Abstract


Ascites is an accumulation of fluid in the peritoneal space and one of the first signs of decompensation of liver disease. Ascites is one of the complications experienced by patients with hepatic cirrhosis. Therapy commonly used for ascites is diuretics, along with salt restriction in the diet. Potassium-sparing diuretics, especially spironolactone and loop diuretics, especially furosemide, are the main pharmacological therapies for ascites. The purpose of this study was to examine the characteristics distribution of hepatic cirrhosis patients, to assess the profile of the use of diuretic drugs during hospitalization, and to determine the possibility of a Drug Related Problem (DRP) on diuretic therapy for patients with ascites at Airlangga University Hospital (RSUA) Surabaya. The research was conducted with non-experimental methods or observations, it was subsequently analyzed descriptively. Data collection was carried out in non-random and time limited sampling in the period of 1 January 2013 - 31 March 2017 in the Inpatient Room of Internal Medicine Department at RSUA Surabaya and was declared as ethically feasible. Based on the results of 45 SH samples with complications of ascites, the most common characteristics of hepatic cirrhosis patients were men by 53.33%, the highest age range was 45-64 years at 75.56%, while the highest complication was hypoalbumin with the percentage of 26.67% and the longest treatment duration was 6-10 days at 46.67%.The therapeutic profile of diuretics in this study, namely the use of furosemide as a single therapy with the percentage of 17.78% and single spironolactone therapy of 2.22% and combination therapy of spironolactone with furosemide with the percentage of 80.00 %. The most widely used furosemide was intravenous use with a daily dose of 1x20mg 57.78%, while spironolactone was the most widely used in oral use with a daily dose of 1x100mg 44.44%. Drug Related Problems (DRP) that occuedr including potential drug interactions found in concomitant use between spironolactone and potassium preparations with the percentage of 24.44%. No actual drug interactions and side effects were found in this study. 


Full Text:

PDF

References


Archer1, M., Brown, C., Hill, C., Steinvoort, C., & Oderda, G. (2015). Drug Class Review Loop Diuretic Agents. Salt Lake City: University of Utah College of Pharmacy, p1-31.

Archer2, M., Steinvoort, C., Oderda, G., (2015). Drug Class Review Potassium-Sparing Diuretic Agents. Salt Lake City: University of Utah College of Pharmacy, p. 1-30.

Biecker, E., (2011). Diagnosis and therapy of asites in liver cirrhosis. World Journal of Gastroenterology, Vol. 17 No. 10, p. 1237-1245.

Dipiro, J., Wells, B., Schwinghammer, T., (2015). Cirrhosis and Portal Hypertension. In: Schwinghammer, T., et al (Eds.). Pharmacotherapy Handbook 9th Ed., New York: McGraw- Hill Education. p. 185-193.

Harlan, E. Ives, (2012). Diuretic Agents. In: Katzung, B. G., Masters, S. B., & Trevor, A. J. (Eds.). Katzung’s Basic & Clinical Pharmacology -12th Ed. New York: McGraw-Hill.

Kusumobroto, Hernomo, O., (2012). Sirosis hati. Dalam: Sulaiman, A. et al. Buku Ajar Ilmu Penyakit Hati. Edisi pertama revisi. Jakarta: Sagung Seto, p. 347-357.

Karin B. Cesario; Anuja Choure; William D. Carey. (2013). Cleveland Clinic Center for Continuing Education. http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/ hepatology/complicatios-of-cirrhosisascites/meds/a682627.html

Muti, A. F., (2011). Sirosis Hati Dengan Komplikasi Asites yang Dirawat di RSUP Dr. Sardjito Yogyakarta. Universitas Gadjah Mada.

Paldosky, D.K., Isselbacher, K.J., Braunwald, E., Martin, J.B., Fauci, A.S., Kasper, L.K., Harisson: Prinsip-prinsip Ilmu Penyakit Dalam. Jakarta: EGC. Halaman 1665-1675

Pedersen, J. S., Bendtsen, F., Møller, S., (2015). Management of cirrhotic asites. Therapeutic Advances in Chronic Disease, Vol. 6 No. 3, p. 124–137.

Perhimpunan Peneliti Hati Indonesia (PPHI), (2013). Asites. http://www.pphi- online.org/alpha/?p=570

Runyon, B. A., (2012). AASLD practice guideline management of adult patients with ascites due to cirrhosis: update 2012. Hepatology, Vol. 57 No. 4, p. 1651–1653.

Tasneem, H., Shahbaz, H., Sherazi, B. A., (2015). Causes, management and complications of asites: a review. International Current Pharmaceutical Journal, Vol. 4 No. 3, p. 370–377. World Health Organization - UPPSALA MONITORING CENTRE., (2016). The use of the WHO-UMC system for standardised case causality assessment. http://www.who.int/medicines/ areas/quality_safety/safety_efficacy/WHOcausality_assessment


Refbacks

  • There are currently no refbacks.